Nephros (NEPH) vs Picard Medical (PMI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nephros (NEPH) has outperformed Picard Medical (PMI) over the past year, losing 46.4% versus a loss of 94.0%. Nephros is the larger company by market cap ($28.4 million vs $18.1 million), about 1.6 times the size. On valuation, Picard Medical trades at a lower trailing P/E (3.0x vs 15.4x for Nephros).
Nephros converts more of its revenue into profit, with a net margin of 6.4% versus -546.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEPH | PMI |
|---|---|---|
| Share price | $2.61 | $6.79 |
| Market cap | $28.37M | $18.07M |
| 1-day change | -8.10% | +7.78% |
| YTD return | -46.52% | -92.24% |
| 1-year return | -46.41% | -94.02% |
| 5-year return | -63.60% | — |
| P/E ratio (TTM) | 15.35 | 3.04 |
| Forward P/E | 11.86 | — |
| EPS (TTM) | $0.17 | $2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $18.79M | $4.94M |
| Revenue growth (YoY) | +32.67% | +12.50% |
| Net income (latest FY) | $1.19M | $-27.00M |
| Gross margin | 61.87% | -4.13% |
| Operating margin | 6.10% | -268.36% |
| Net margin | 6.35% | -546.60% |
| 52-week high | $6.42 | $208.00 |
| 52-week low | $2.61 | $2.65 |
| Distance from 52-week high | -59.35% | -96.74% |
| Analyst consensus | none | — |
| Avg. price target upside | +139.46% | — |
| Average volume | 48.33K | 1.45M |
| Shares outstanding | 10.87M | 2.66M |
| Employees | 36 | 75 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEPH has outperformed PMI by 47.6 percentage points over the past year.
- Nephros trades at a higher earnings multiple (15.4x vs 3.0x trailing P/E).
- Nephros is more profitable, keeping 6.4 cents of every revenue dollar as net income versus -546.6 cents for Picard Medical.
- Nephros grew revenue faster in its latest fiscal year (+32.67% vs +12.50%).
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
About Picard Medical
PMI stock →Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure.
Health Care · Medical/Dental Instruments · 75 employees
NEPH vs PMI FAQ
Which is bigger, Nephros or Picard Medical?
Nephros (NEPH) is larger, with a market capitalization of $28.37M compared with $18.07M for Picard Medical (PMI).
Which stock has performed better over the past year, NEPH or PMI?
NEPH returned -46.41% over the past 12 months, compared with -94.02% for PMI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NEPH or PMI?
PMI has the lower trailing P/E at 3.0, versus 15.4 for NEPH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Nephros and Picard Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.